Danaher to Acquire Masimo in $9.9B Diagnostics Deal

Danaher has agreed to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at about $9.9 billion including debt and acquired cash. The deal is expected to close in the second half of 2026, subject to regulatory and shareholder approvals.

After closing, Masimo will operate as a standalone company within Danaher’s Diagnostics segment alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Danaher expects Masimo to contribute between $0.15 and $0.20 to adjusted diluted earnings per share in the first full year and roughly $0.70 by year five, with long-term high-single-digit revenue growth.

Danaher projects Masimo will generate more than $530 million in EBITDA in 2027 and anticipates over $125 million in annual cost synergies plus more than $50 million in revenue synergies within five years of closing.